Phase I study of nivolumab or nivolumab/cisplatin/gemcitabine to treat unresectable/recurrent biliary tract cancer

被引：0
|
作者：
Morizane, Chigusa [1 ]
Ikeda, Masafumi [2 ]
Ueno, Makoto [3 ]
Kobayashi, Satoshi [3 ]
Ohno, Izumi [2 ]
Kondo, Shunsuke [1 ]
Okano, Naohiro [4 ]
Kimura, Keisuke [5 ]
Asada, Suguru [5 ]
Namba, Yoshinobu [5 ]
Okusaka, Takuji [1 ]
Furuse, Junji [4 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[4] Kyorin Univ, Fac Med, Mitaka, Tokyo, Japan
[5] Ono Pharmaceut Co Ltd, Osaka, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz339.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O2 - 2 - 4
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [31] A phase I study of ADH-1 with cisplatin (Cisp) and gemcitabine (Gem) in patients (Pts) with unresectable or metastatic pancreatic and biliary tract cancers
    Berim, Lyudmyla Derby
    Kos, Beth M.
    Evande, Ruby
    Meza, Jane L.
    Shostrom, Valerie
    Schwarz, James K.
    Grem, Jean L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [32] A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer
    Tsuyoshi Hayashi
    Hirotoshi Ishiwatari
    Makoto Yoshida
    Tsutomu Sato
    Koji Miyanishi
    Yasushi Sato
    Masayoshi Kobune
    Rishu Takimoto
    Tomoko Sonoda
    Junji Kato
    International Journal of Clinical Oncology, 2012, 17 : 491 - 497
  • [33] A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer
    Hayashi, Tsuyoshi
    Ishiwatari, Hirotoshi
    Yoshida, Makoto
    Sato, Tsutomu
    Miyanishi, Koji
    Sato, Yasushi
    Kobune, Masayoshi
    Takimoto, Rishu
    Sonoda, Tomoko
    Kato, Junji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (05) : 491 - 497
  • [34] Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study
    Gruenberger, Birgit
    Schueller, Johannes
    Heubrandtner, Ute
    Wrba, Fritz
    Tamandl, Dietmar
    Kaczirek, Klaus
    Roka, Rudolf
    Pircher, Sandra Freimann
    Gruenberger, Thomas
    LANCET ONCOLOGY, 2010, 11 (12): : 1142 - 1148
  • [35] Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab
    Ishido, Kenji
    Tanabe, Satoshi
    Katada, Chikatoshi
    Ishibashi, Yu
    Kitahara, Gen
    Onoue, Mie
    Kubota, Yo
    Furue, Yasuaki
    Wada, Takuya
    Watanabe, Akinori
    Kusano, Chika
    JOURNAL OF GASTROINTESTINAL CANCER, 2023, 54 (02) : 485 - 491
  • [36] Phase I Study of Stereotactic Body Radiotherapy followed by Ipilimumab with Nivolumab vs. Nivolumab alone in Unresectable Hepatocellular Carcinoma
    Juloori, A.
    Liao, C. Y.
    Lemons, J. M.
    Singh, A. K.
    Iyer, R.
    Robbins, J. R.
    George, B.
    Fung, J.
    Pillai, A.
    Arif, F.
    Sharma, M.
    Liauw, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S149 - S150
  • [37] Gemcitabine alone or plus cisplatin for biliary tract cancer?
    Scheithauer, Werner
    NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (10) : 554 - 555
  • [38] Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab
    Kenji Ishido
    Satoshi Tanabe
    Chikatoshi Katada
    Yu Ishibashi
    Gen Kitahara
    Mie Onoue
    Yo Kubota
    Yasuaki Furue
    Takuya Wada
    Akinori Watanabe
    Chika Kusano
    Journal of Gastrointestinal Cancer, 2023, 54 : 485 - 491
  • [39] A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer
    Chiang, N-J.
    Bai, L-Y.
    Huang, C-J.
    Chen, S-C.
    Hsiao, C-F.
    Shan, Y-S.
    Su, Y-Y.
    Chen, L.
    Chen, M-H.
    ANNALS OF ONCOLOGY, 2021, 32 : S377 - S377
  • [40] Gemcitabine alone or plus cisplatin for biliary tract cancer?
    Werner Scheithauer
    Nature Reviews Clinical Oncology, 2010, 7 : 554 - 555
12345